Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice
Joint Authors
Hortobágyi, Tibor
Gergely, Péter Attila
Murnyák, Balázs
Bencze, János
Kurucz, Andrea
Varjas, Timea
Gombos, Katalin
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-02-07
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Tyrosine kinases play crucial roles in cellular development and tumorigenesis.
Tyrosine kinase inhibitors (TKIs) are effective and widely used drug molecules in targeted cancer therapies.
Altered expressions of protooncogenes and tumor suppressor genes after DMBA (7,12-dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction; however their tissue-specific effects remain still unclear.
Our study was aimed at examining the short-term possible antineoplastic and chemopreventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model.
In addition, we also investigated the tissue-specific expressions of Hras, Kras, Myc, and Trp53 genes in the brain, bone marrow, spleen, liver, abdominal lymph nodes, thymus, lungs, and kidneys, respectively.
24 hours after the imatinib mesylate injection, we observed significant Kras downregulation in the bone marrow and lung of the DMBA-treated mice.
Moreover, the mRNA expression of Myc was also found to be decreased significantly in the spleen.
Interestingly, while Trp53 expression was significantly increased in the lung, it was decreased in the other tissues.
However, there was also a tendency in the decreased Myc level in the bone marrow, brain, kidneys, lungs, and lymph nodes and in the decreased Hras level in the bone marrow, kidneys, and lungs, although no significant differences were observed.
Our findings indicate rapid tissue-specific impact of imatinib mesylate on DMBA-induced gene expression in vivo, supporting the chemopreventive potential of imatinib mesylate in cancer.
American Psychological Association (APA)
Gergely, Péter Attila& Murnyák, Balázs& Bencze, János& Kurucz, Andrea& Varjas, Timea& Gombos, Katalin…[et al.]. 2019. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International،Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
Modern Language Association (MLA)
Gergely, Péter Attila…[et al.]. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International No. 2019 (2019), pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
American Medical Association (AMA)
Gergely, Péter Attila& Murnyák, Balázs& Bencze, János& Kurucz, Andrea& Varjas, Timea& Gombos, Katalin…[et al.]. Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early OncoSuppressor Gene Expression with Tissue-Specificity in Mice. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1128062
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1128062